过去一年中添加的文章,按日期排序

Effects of Dapagliflozin on Body Composition and Its Relation to Hemodynamics in Heart Failure With Preserved Ejection Fraction

JA Naser, A Tada, T Harada, YNV Reddy, RE Carter… - Circulation, 2024 - Am Heart Assoc
8 天前 - … -2 inhibitor dapagliflozinDAPA, 5 we evaluated the effect of dapagliflozin on
body and blood composition and examined the potential correlation of such changes on cardiac

[HTML][HTML] Assessment of a systematic approach for implementing novel medications in clinical practice: an observational study with dapagliflozin

H Norberg, T Andersson, E Håkansson… - European Journal of …, 2024 - Springer
15 天前 - … of the phase III trials DAPA-HF and DELIVER [20, 26], suggesting that the safety
characteristics observed with dapagliflozin could be applicable to our heart failure cohort. …

[HTML][HTML] CVOT Summit Report 2023

O Schnell - diabetologie-online.de
21 天前 - … on recently completed outcomes trials including dapagliflozin (DAPA-MI), semaglutide
(… cardiovascular disease (CVD) in diabetes, heart failure (HF) and chronic kidney disease

Patient Selection Is the Key to EMPACTing Development of Heart Failure After Myocardial Infarction

A Kochar, R Gattani, M Vaduganathan - Journal of the American College of …, 2024 - jacc.org
22 天前 - … Post myocardial infarction (MI) heart failure (HF) remains highly prevalent and
strongly … and chronic symptomatic heart failure Dapagliflozin 11.6 mo 1.3% dapagliflozin vs …

Empowering European hospital pharmacists in the face of heart failure

L Defieuw, J Hias, F Karapinar-Carkıt… - European Journal of …, 2024 - ejhp.bmj.com
43 天前 - … of Adverse Outcomes in Heart Failure (DAPA-HF) study … ambulatory chronic HF
patients who received dapagliflozin. … acute HF episode, constituting up to 25% of all HF patients. …

[HTML][HTML] A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials

T Kondo, PS Jhund, SB Gasparyan, M Yang… - Nature Medicine, 2024 - nature.com
51 天前 - dapagliflozin to placebo in patients with heart failure and reduced ejection fraction
(DAPA-HF) and … The effect of dapagliflozin on a hierarchical composite kidney outcome was …

Dapagliflozin and quality of life measured using the EuroQol 5‐dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved …

M Yang, T Kondo, A Talebi, PS Jhund… - … of Heart Failure, 2024 - Wiley Online Library
53 天前 - DAPA-HF and DELIVER trials, which investigated the effectiveness and safety of
dapagliflozin in patients with HFPatients reporting higher (better) EQ-5D-5L VAS and index …

Current use of Sodium Glucose Co-transporter 2 Inhibitors in Heart Failure Therapy

Y Çavuşoğlu, H Altay, A Çelik, TS Güvenç… - Archives of the Turkish … - archivestsc.com
77 天前 - DAPA-HF and EMPEROR-Reduced trials in HFrEF patients with or without T2DM,
SGLT2is, dapagliflozin and empagliflozin treatment on top of standard HF therapy has been …

Η χρήση των SGLT2 αναστολέων σε μη διαβητικούς ασθενείς με καρδιακή ανεπάρκεια και μειωμένο κλάσμα εξώθησης

Α Κοκκάλη - repo.lib.duth.gr
79 天前 - … in Heart Failure (DAPA-HF) trial and the Cardiovascular and Renal Outcomes trial
with Empagliflozin in Heart Failure (… of dapagliflozin and empagliflozin for both nondiabetic …

Sotagliflozin versus dapagliflozin to improve outcome of patients with diabetes and worsening heart failure: a cost per outcome analysis

W Zhang, M Yu, G Cheng - Frontiers in Pharmacology, 2024 - frontiersin.org
82 天前 - … Based on DAPA-HF, this study investigated the cost-effectiveness of dapagliflozin
compared to a placebo among heart failure patients with diabetes. This finding demonstrated …